The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry

Andrea R. Masters, Christopher J. Sweeney, David R. Jones

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI-420, in plasma. The advantages of this method include the use of a small sample volume, liquid-liquid extraction with high extraction efficiency and short chromatographic run times. The analytes were extracted from 100 μL plasma volume using hexane:ethyl acetate after midazolam was added to the sample for internal standardization. The compounds were separated on a Phenomenex C-18 Luna analytical column with acetonitrile:5 mM ammonium acetate as the mobile phase. All compounds were monitored by tandem mass spectrometry with electrospray positive ionization. The intra-day accuracy and precision (% coefficient of variation, % CV) estimates for erlotinib at 10 ng/mL were 90% and 9%, respectively. The intra-day accuracy and precision estimates for OSI-420 at 5 ng/mL were 80% and 4%, respectively. This method was used to quantify erlotinib and OSI-420 in plasma of patients (n = 21) administered 150 mg erlotinib per day for non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume848
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Plasma (human)
Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Mass spectrometry
Plasmas
Liquid-Liquid Extraction
Plasma Volume
Midazolam
Liquids
Hexanes
Metabolites
Non-Small Cell Lung Carcinoma
Standardization
Ionization
High Pressure Liquid Chromatography
Cells
OSI-420
Erlotinib Hydrochloride

Keywords

  • Erlotinib
  • HPLC-MS/MS
  • OSI-774

ASJC Scopus subject areas

  • Biochemistry

Cite this

The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. / Masters, Andrea R.; Sweeney, Christopher J.; Jones, David R.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 848, No. 2, 01.04.2007, p. 379-383.

Research output: Contribution to journalArticle

@article{1fe0c184cd044b21b0272efbe685f7da,
title = "The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry",
abstract = "An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI-420, in plasma. The advantages of this method include the use of a small sample volume, liquid-liquid extraction with high extraction efficiency and short chromatographic run times. The analytes were extracted from 100 μL plasma volume using hexane:ethyl acetate after midazolam was added to the sample for internal standardization. The compounds were separated on a Phenomenex C-18 Luna analytical column with acetonitrile:5 mM ammonium acetate as the mobile phase. All compounds were monitored by tandem mass spectrometry with electrospray positive ionization. The intra-day accuracy and precision ({\%} coefficient of variation, {\%} CV) estimates for erlotinib at 10 ng/mL were 90{\%} and 9{\%}, respectively. The intra-day accuracy and precision estimates for OSI-420 at 5 ng/mL were 80{\%} and 4{\%}, respectively. This method was used to quantify erlotinib and OSI-420 in plasma of patients (n = 21) administered 150 mg erlotinib per day for non-small cell lung cancer.",
keywords = "Erlotinib, HPLC-MS/MS, OSI-774",
author = "Masters, {Andrea R.} and Sweeney, {Christopher J.} and Jones, {David R.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.jchromb.2006.10.046",
language = "English (US)",
volume = "848",
pages = "379--383",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry

AU - Masters, Andrea R.

AU - Sweeney, Christopher J.

AU - Jones, David R.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI-420, in plasma. The advantages of this method include the use of a small sample volume, liquid-liquid extraction with high extraction efficiency and short chromatographic run times. The analytes were extracted from 100 μL plasma volume using hexane:ethyl acetate after midazolam was added to the sample for internal standardization. The compounds were separated on a Phenomenex C-18 Luna analytical column with acetonitrile:5 mM ammonium acetate as the mobile phase. All compounds were monitored by tandem mass spectrometry with electrospray positive ionization. The intra-day accuracy and precision (% coefficient of variation, % CV) estimates for erlotinib at 10 ng/mL were 90% and 9%, respectively. The intra-day accuracy and precision estimates for OSI-420 at 5 ng/mL were 80% and 4%, respectively. This method was used to quantify erlotinib and OSI-420 in plasma of patients (n = 21) administered 150 mg erlotinib per day for non-small cell lung cancer.

AB - An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI-420, in plasma. The advantages of this method include the use of a small sample volume, liquid-liquid extraction with high extraction efficiency and short chromatographic run times. The analytes were extracted from 100 μL plasma volume using hexane:ethyl acetate after midazolam was added to the sample for internal standardization. The compounds were separated on a Phenomenex C-18 Luna analytical column with acetonitrile:5 mM ammonium acetate as the mobile phase. All compounds were monitored by tandem mass spectrometry with electrospray positive ionization. The intra-day accuracy and precision (% coefficient of variation, % CV) estimates for erlotinib at 10 ng/mL were 90% and 9%, respectively. The intra-day accuracy and precision estimates for OSI-420 at 5 ng/mL were 80% and 4%, respectively. This method was used to quantify erlotinib and OSI-420 in plasma of patients (n = 21) administered 150 mg erlotinib per day for non-small cell lung cancer.

KW - Erlotinib

KW - HPLC-MS/MS

KW - OSI-774

UR - http://www.scopus.com/inward/record.url?scp=33947541184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947541184&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2006.10.046

DO - 10.1016/j.jchromb.2006.10.046

M3 - Article

C2 - 17101305

AN - SCOPUS:33947541184

VL - 848

SP - 379

EP - 383

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 2

ER -